Free Trial

Smith & Nephew (SN) Stock Forecast & Price Target

GBX 1,100
+9.00 (+0.82%)
(As of 07/12/2024 ET)

Smith & Nephew - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

GBX 1,346.20
High ForecastGBX 1,500
Average ForecastGBX 1,346.20
Low ForecastGBX 1,150
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 1,346.20GBX 1,346.20GBX 1,362.50GBX 1,437
Get Smith & Nephew Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter.

SN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Smith & Nephew Stock vs. The Competition

TypeSmith & NephewMedical Companies
Consensus Rating Score
2.80
2.71
Consensus RatingModerate BuyModerate Buy
News Sentiment RatingNeutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/7/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperformGBX 1,500+50.48%
5/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 1,250+26.83%
5/2/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweightGBX 1,300 ➝ GBX 1,381+41.41%
5/2/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 1,450+48.47%
2/9/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual WeightGBX 1,150+4.40%
6/15/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
3/1/2023Liberum Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeBuyGBX 1,120 ➝ GBX 1,410+18.89%
8/4/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperformGBX 1,540 ➝ GBX 1,400+33.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:40 AM ET.

SN Forecast - Frequently Asked Questions

What is Smith & Nephew's forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Smith & Nephew is GBX 1,346.20, with a high forecast of GBX 1,500 and a low forecast of GBX 1,150.

Should I buy or sell Smith & Nephew stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SN shares.

Does Smith & Nephew's stock price have much upside?

According to analysts, Smith & Nephew's stock has a predicted upside of 33.63% based on their 12-month stock forecasts.

What analysts cover Smith & Nephew?

Smith & Nephew has been rated by research analysts at Berenberg Bank, Jefferies Financial Group, JPMorgan Chase & Co., and Royal Bank of Canada in the past 90 days.

Do Wall Street analysts like Smith & Nephew more than its competitors?

Analysts like Smith & Nephew more than other "medical" companies. The consensus rating score for Smith & Nephew is 2.80 while the average consensus rating score for "medical" companies is 2.71. Learn more on how SN compares to other companies.


This page (LON:SN) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners